NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis
Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis

NCT06590428

RecruitingNA

Sponsor: Albert Einstein College of Medicine

Conditions: Rifampin-resistant Tuberculosis, Drug-resistant Tuberculosis

Interventions: Therapeutic Drug Monitoring for Linezolid

Countries: South Africa

This study is a two-arm, pragmatic, open-label, randomized clinical trial to determine the efficacy of Therapeutic Drug Monitoring (TDM) in preventing premature discontinuation of Linezolid (LZD) in participants with Rifampicin-resistant tuberculosis (RR-TB). Following the initiation of treatment, participants will be monitored throughout the approximate 6-month duration of RR-TB therapy.

Eligibility overview

Sex: ALL

Age: 18 Years to

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Adult male or female patient \> 18 years of age
* Microbiological confirmation of rifampicin-resistant tuberculosis (e.g., phenotypic or genotypic drug susceptibility testing, GeneXpert MTB/RIF™). Participants may have resistance to additional medications as well - i.e., MDR and XDR TB - but must have resistance to at least rifampin
* Initiated on a rifampicin-resistant tuberculosis (RR-TB) treatment regimen containing linezolid, no more than 14 days prior to randomization
* HIV status is known and confirmed

  * Both HIV-positive and HIV-negative individuals are eligible
  * If an individual reports unknown HIV status, they must consent to HIV testing at time of enrollment to confirm status. If they decline to be tested, they are not eligible for the study

Exclusion Criteria:

* Severe medical condition with expected death in the next 7 days
* Pregnant at time of screening
* Initial linezolid dose \< 600mg daily
* Severe form of extrapulmonary TB (i.e., meningitis, pericarditis, or osteomyelitis)
* Unlikely to follow-up at Nkqubela Hospital based on location of residence
Locations (1)
  • East London, Eastern Cape, South Africa